Clinical disclaimer: This content is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not approved by the FDA. Treatment decisions should be made with a licensed medical provider based on your individual health status. Moonshot Medical does not prescribe retatrutide.
Retatrutide
SHOULD YOU WAIT FOR RETATRUTIDE?
Or should you start semaglutide or tirzepatide now? A clinical framework for making the decision.
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC · Updated March 25, 2026
THE SHORT ANSWER
If you meet criteria for GLP-1 treatment today, start today. Don't delay proven, FDA-approved treatment for 1–2 years waiting for a drug that hasn't been approved yet.
Retatrutide is promising. The Phase 2 data is impressive — up to 24% body weight loss at 48 weeks. The triple-agonist mechanism (GLP-1 + GIP + glucagon) offers something genuinely new. But "promising Phase 2 data" and "available medication you can take tomorrow" are not the same thing.
Semaglutide and tirzepatide are FDA-approved, extensively studied, widely available, and producing life-changing results for patients right now. Retatrutide is none of those things yet.
You can always switch later. Starting now does not lock you in. It means you spend the next 12–24 months improving your health instead of waiting to improve your health.
The bottom line: The best GLP-1 medication is the one that's FDA-approved, available, and in your body working — not the one you're reading about in a press release.
THE CASE FOR STARTING NOW
Obesity is not a cosmetic problem you can put on hold. It's a progressive metabolic disease. Every month untreated is a month of compounding damage across multiple systems.
You Have Conditions Today
If your BMI is 30+ or 27+ with a comorbidity like Type 2 diabetes, hypertension, dyslipidemia, or sleep apnea — those conditions are actively damaging your cardiovascular system, joints, liver, and metabolic function right now. Not in the future. Right now. Every week you wait is a week those conditions progress unchecked.
Metabolic Damage Compounds
Insulin resistance begets more insulin resistance. Visceral fat drives inflammation, which drives more visceral fat accumulation. Elevated blood pressure damages arterial walls, leading to atherosclerotic plaque that doesn't reverse easily. Fatty liver progresses through stages — steatosis to NASH to fibrosis. The earlier you intervene, the more reversible the damage is. Wait too long and some of it becomes permanent.
Cardiovascular Risk Accumulates Daily
The STEP-HFpEF and SELECT trials demonstrated that semaglutide reduces major adverse cardiovascular events by 20%. That cardiovascular protection starts when you start the medication. Every month you delay is a month without that risk reduction. Heart attacks and strokes don't wait for the next drug to be approved.
Joint Deterioration Is Not Reversible
Excess weight accelerates osteoarthritis. The cartilage damage is mechanical and irreversible. Losing weight reduces the load and slows progression. Every pound of body weight creates roughly 4 pounds of force across the knee joint during walking. Starting treatment now protects joints you can't replace (or at least delays the replacement).
Quality of Life Cost Is Real
Energy levels, sleep quality, mobility, confidence, libido, mental health — these improve meaningfully within the first 2–3 months of GLP-1 treatment. That's not a trivial benefit to defer. Eighteen months of feeling better versus eighteen months of waiting to feel better is a significant quality-of-life difference.
Approved Medications Work
Semaglutide produces 15–20% body weight loss. Tirzepatide produces 20–25%. These are not marginal results. For a 250-pound patient, that's 37–62 pounds of weight loss with proven cardiovascular, metabolic, and quality-of-life benefits. Waiting for potentially 24% instead of 22% while carrying those 250 pounds is not a rational trade-off.
The uncomfortable truth: Retatrutide is not guaranteed to be approved. Phase 3 trials can fail. Safety signals can emerge at scale. Manufacturing and supply chain issues can delay launch by years. Pricing could make it inaccessible. Building your health plan around an investigational drug's timeline is speculative — treating a disease you have today with a medication that works today is medicine.
THE CASE FOR WATCHING AND WAITING
Waiting isn't always wrong. For some people, it's the right call. The key is whether you actually need treatment now or you're in a position where deferring carries minimal risk.
When waiting is reasonable:
- • You're early in your weight loss journey. BMI in the 25–27 range, no metabolic comorbidities, and you haven't exhausted lifestyle interventions. GLP-1 medications are powerful tools — but if diet, exercise, and behavioral changes haven't been seriously attempted yet, that's the appropriate first line.
- • You're not at a point where medication is clearly indicated. The clinical threshold for GLP-1 therapy is BMI 30+ or BMI 27+ with a comorbidity. If you don't meet that threshold, you're in a gray area where the risk-benefit calculus is different.
- • You want to see the data mature. Retatrutide's Phase 2 results are impressive, but Phase 2 trials are small. Phase 3 will tell us about efficacy at scale, long-term safety, and how it performs in diverse populations. If you're the type who wants to see the full data before committing, that's a valid stance — as long as you're not using it as a reason to avoid treatment you need.
- • You're already at a healthy weight but interested in optimization. If you're curious about GLP-1s for body recomposition or longevity reasons rather than medical necessity, there's no urgency. Watch the data develop. There's no cost to waiting when there's no disease to treat.
The honest version: waiting is fine when the condition you're waiting to treat isn't actively harming you. The problem is that most people asking "should I wait for retatrutide?" are asking because they need treatment now and are looking for a reason to delay — and the next generation's hype cycle provides a convenient one.
WHEN RETATRUTIDE MIGHT BE WORTH WAITING FOR
Retatrutide isn't just "more of the same." Its triple-agonist mechanism — adding glucagon receptor activation to the GLP-1/GIP backbone — opens pathways that existing medications don't address. There are specific clinical scenarios where that matters.
Significant Fatty Liver Disease (MASLD/NASH)
This is where retatrutide's data is most differentiated. The glucagon receptor agonism drives hepatic fat oxidation — essentially telling the liver to burn its stored fat directly. Phase 2 data showed an 86% relative reduction in liver fat at 48 weeks. Semaglutide and tirzepatide reduce liver fat too, but through a more indirect pathway (total weight loss reduces visceral/hepatic fat as a downstream effect). If you have advanced fatty liver disease, retatrutide's mechanism may offer a meaningfully different benefit.
However: If your liver disease is progressing now, start treatment now with available options. Don't let your liver fibrosis advance while waiting for a better liver drug. You can switch later.
Plateaued on Semaglutide or Tirzepatide
If you're already on a GLP-1 and have hit a sustained plateau — weight loss has stalled for 3+ months despite adherence and dose optimization — the glucagon mechanism offers a genuinely different metabolic lever. It increases resting energy expenditure in a way that GLP-1 and GIP alone don't. For patients who've gotten significant benefit but have stalled, retatrutide could represent a meaningful step forward rather than just a lateral move.
Body Composition Is the Primary Concern
Early data suggests retatrutide's glucagon component may preferentially target fat loss while relatively preserving lean mass compared to GLP-1-only approaches. The mechanism makes biological sense: glucagon promotes lipolysis and fatty acid oxidation while being less catabolic to muscle than pure caloric restriction. If your primary goal is body recomposition rather than scale weight, and you're already lean enough that a standard GLP-1 isn't clearly indicated, this is the scenario where tracking the data makes the most sense.
Notice the pattern: In each scenario, the advice is still "start treatment if you need it now" or "continue your current treatment." Retatrutide is a future option to switch to or add, not a reason to sit in the waiting room of your own health.
WHAT SWITCHING LOOKS LIKE
One of the biggest misconceptions driving the "wait for retatrutide" mentality is the assumption that starting one GLP-1 medication locks you in. It doesn't.
Patients already switch between semaglutide and tirzepatide routinely. Reasons include inadequate response, intolerable side effects, insurance changes, or simply trying a different mechanism to break through a plateau. The switching process is well-established.
When retatrutide is approved, adding it as a third option doesn't fundamentally change that dynamic. The likely switching protocol will involve:
- 1. Clinical evaluation — Review your current response, side effect profile, metabolic markers, and goals to determine if switching is appropriate.
- 2. Dose mapping — Starting dose of retatrutide calibrated based on your current GLP-1 dose and tolerance. You likely won't restart from the lowest dose.
- 3. Titration period — Gradual dose adjustment over 4–8 weeks to find your optimal retatrutide dose, just like the initial titration on any GLP-1.
- 4. Monitoring — Labs and body composition tracking to confirm the switch is producing the intended benefit.
Important caveat: No clinical data on semaglutide/tirzepatide-to-retatrutide transitions exists yet because retatrutide isn't approved. The protocol above is based on the shared receptor mechanisms and clinical experience with inter-GLP-1 switching. The exact approach will be refined once post-market data is available.
The point: starting semaglutide or tirzepatide now doesn't close the door on retatrutide later. It opens the door on treatment today and keeps all future options available.
A DECISION FRAMEWORK
Instead of debating "retatrutide vs. current options" in the abstract, use your clinical situation to determine the right path.
Your Situation
BMI ≥30, or ≥27 with metabolic comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea)
Recommendation
Start now with semaglutide or tirzepatide. You meet clinical criteria for treatment. Evaluate retatrutide when it's available and you've established your response to current options.
Your Situation
Significant MASLD/NASH (fatty liver disease confirmed on imaging or biopsy)
Recommendation
Start now. Treat the liver disease with what's available. Consider switching to retatrutide when approved — its glucagon-driven hepatic fat reduction may offer superior liver-specific outcomes.
Your Situation
Currently on semaglutide or tirzepatide and plateaued for 3+ months
Recommendation
Continue current medication. Optimize dose, protein intake, and exercise. Evaluate switching to retatrutide at approval — the glucagon mechanism may break through the plateau via increased energy expenditure.
Your Situation
Early research phase — BMI 25–27, no comorbidities, lifestyle changes not yet fully attempted
Recommendation
Track the data, start when ready. Focus on nutrition, exercise, and metabolic health fundamentals. Get baseline labs and DEXA. Revisit medication when you've given lifestyle a serious effort or if your clinical picture changes.
Your Situation
Already at goal weight — interested in optimization, not medical necessity
Recommendation
No urgency for any GLP-1. You're not in a position where waiting costs you anything. Let the data mature. Focus on body composition monitoring, bloodwork optimization, and the fundamentals that compound over time.
The pattern is clear: In every scenario where treatment is indicated, the answer is "start now." In every scenario where treatment isn't clearly indicated, the answer is "no urgency for any GLP-1" — not just retatrutide. The drug you're waiting for isn't the variable. Whether you need treatment is the variable.
WHAT MOONSHOT OFFERS TODAY
We prescribe and manage semaglutide and tirzepatide as part of a comprehensive metabolic health program. Not a telehealth prescription mill. Not a "get your Ozempic here" vending machine. A full clinical program designed to maximize results and protect your health throughout the process.
GLP-1 Medications
Semaglutide and tirzepatide prescribed and managed by board-certified providers. Dose titration based on your response, not a one-size-fits-all protocol. Side effect management. Insurance navigation support.
DEXA Body Composition
Clinical-grade DEXA scanning to track fat loss vs. muscle loss throughout treatment. This is how you know if your protocol is working correctly — the scale alone doesn't tell you enough.
Comprehensive Blood Work
Metabolic panels, lipids, inflammatory markers, hormones, and metabolic health indicators. Baseline and follow-up testing to track the systemic improvements that weight loss alone doesn't capture.
Full Metabolic Program
Nutrition guidance, exercise recommendations (especially strength training to preserve muscle), ongoing provider check-ins, and protocol adjustments based on your data. The medication is one tool in a system, not the whole system.
On retatrutide: When retatrutide receives FDA approval and we've reviewed the post-market safety data, we'll add it to our formulary for patients where it's clinically appropriate. We'll help existing patients evaluate whether switching makes sense for their specific situation. That's the advantage of being in an active treatment program — you have a provider who knows your history and can make that call with you.
FREQUENTLY ASKED QUESTIONS
Should I wait for retatrutide before starting GLP-1 treatment?
If you meet clinical criteria for GLP-1 therapy now (BMI 30+ or BMI 27+ with a metabolic comorbidity), starting with an FDA-approved medication like semaglutide or tirzepatide is the stronger clinical decision. Retatrutide is still in Phase 3 trials, with FDA approval likely 1–2 years away at earliest. Every month of untreated obesity carries compounding metabolic, cardiovascular, and joint risk. You can always switch to retatrutide once it's available.
Can I switch from semaglutide or tirzepatide to retatrutide later?
Most likely, yes. No clinical data on transitions exists yet since retatrutide is not FDA-approved, but based on the shared GLP-1 receptor mechanism, switching should be feasible with appropriate dose titration. Patients already switch between semaglutide and tirzepatide routinely. Adding a third option doesn't fundamentally change that process.
Is retatrutide definitely going to be approved?
Nothing is guaranteed until the FDA issues approval. Phase 2 results were strong — up to 24% body weight loss at 48 weeks. Phase 3 trials are underway. But Phase 3 failures happen. Safety signals can emerge. Manufacturing issues can delay timelines. Regulatory decisions are unpredictable. Planning your health around an unapproved drug's timeline is not a sound strategy.
Will retatrutide be covered by insurance?
Unknown. Insurance coverage for GLP-1 medications is already inconsistent — many plans exclude weight loss indications entirely, even for FDA-approved drugs like Wegovy and Zepbound. A new, likely premium-priced medication faces the same coverage battles. Early availability will almost certainly be out-of-pocket or limited to specific plans.
What if I'm already on Mounjaro (tirzepatide) — should I switch to retatrutide when it's available?
If tirzepatide is working well for you — producing steady weight loss, manageable side effects, improving metabolic markers — there's no clinical reason to switch to a newer drug just because it's newer. Consider retatrutide if you've plateaued on tirzepatide, if you have significant fatty liver disease (retatrutide's glucagon agonism shows strong liver data), or if body composition rather than pure weight loss is your primary remaining goal.
References
- 1. Jastreboff AM, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." N Engl J Med. 2023;389(6):514-526.
- 2. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021;384:989-1002. (STEP 1)
- 3. Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387:205-216. (SURMOUNT-1)
- 4. Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity." N Engl J Med. 2023;389:2221-2232. (SELECT)
- 5. Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease." Nat Med. 2024;30:2037-2048.
- 6. Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist." Cell Metab. 2022;34(9):1234-1247.
- 7. ClinicalTrials.gov: NCT05929066 (TRIUMPH Phase 3 program).
READY TO START?
Don't wait for the next drug. Start with what works today. We'll help you find the right medication, build a protocol around your goals, and track your results with real data.